Evidence map›Paper›PMID 42221150›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026

GLP-1 Receptor Agonists Reduce Aortic Dissection and Hypertensive Crisis in Diabetic Patients with Aortic Aneurysm: A Retrospective Cohort Study.

Yung-Fong Tsai, Huan-Tang Lin, Yu-Fang Liu, Renin Chang, Shao-Chun Wu

Abstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yung-Fong TsaiDepartment of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.ORCID 0000-0002-3121-4840
Huan-Tang LinDepartment of Anesthesiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.ORCID 0000-0001-6411-7978
Yu-Fang LiuDepartment of Anesthesiology, China Medical University Hospital, Taichung, Taiwan.
Renin Chang *Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Shao-Chun Wu *College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-0984-6921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Aortic aneurysm rupture and dissection carry mortality exceeding 50%, yet evidence-based medical therapies for this high-risk population remain limited. Despite mechanistic evidence suggesting glucagon-like peptide-1 receptor agonists (GLP-1RAs) stabilize vascular inflammation, no large-scale study has evaluated their impact on acute aortic events in diabetic patients with pre-existing aortic aneurysm. Methods: This retrospective active-comparator new-user cohort study utilized TriNetX data from 152 US healthcare organizations (2016-2023). A total of 11,581 adults with type 2 diabetes and documented non-ruptured aortic aneurysm initiating GLP-1RA (n=5676) or dipeptidyl peptidase-4 inhibitors (DPP-4i; n=5905) were identified. DPP-4i was selected as the active comparator given its documented cardiovascular neutrality, whereas sodium-glucose cotransporter-2 inhibitors were not used as a comparator due to their established cardiovascular benefits. After 1:1 propensity-score matching, 3857 patients per group were analyzed using Cox proportional hazards models. Results: GLP-1RA therapy was associated with lower risks of aortic rupture/dissection requiring surgical repair (hazard ratio [HR] 0.75, 95% CI 0.60-0.94; Conclusion: In diabetic patients with pre-existing aortic aneurysm, GLP-1RA therapy was associated with lower incidence of aortic rupture/dissection, hypertensive crisis, and mortality compared with DPP-4i, supporting preferential consideration of GLP-1RA in this high-risk population.

Indexed as

aortic aneurysmaortic dissectioncardiovascular outcomesdiabetes mellitusglucagon-like peptide-1 receptor agonistreal-world evidence

Identifiers

PMID42221150
PMCPMC13217444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.